At an online press conference on the acquisition of a new German production site, EXECUTIVE Director Ugur Sahin said tests had recently shown that the genetic compound remained solid between 2 and 8 degrees Celsius for five days, but expects the garage’s capacity in such situations to increase. Be two weeks or more.
He added that a smart vaccine was at least 70% to 75% effective at quelling the pandemic and that this was also the criterion that BioNTech had set.
BioNTech SE has announced that it will acquire a German production plant capable of generating 750 million doses according to the year of its Covid-19 vaccine, more than double the amount the company can produce as it prepares to supply the world with its unproven vaccine. . .
The acquisition of the site from Swiss pharmaceutical giant Novartis AG shows German biotechnology’s confidence in the experimental vaccine that is emerging in collaboration with his US wife Pfizer Inc and Shanghai Fosun Pharmaceutical Group Co. China in expanding existing sites, as he had done. general manager Ugur Sahin said.
“Especially in the first part of 2021, we can get more doses than expected,” Sahin said.
BioNTech’s vaccine candidate and rivals are making their way through clinical studies amid intense public scrutiny and, in some countries, political promises in the United States, Paul Mango, one of the leaders of the administration’s Covid-19 vaccination program, said Wednesday that each and every American can be vaccinated until the end of March.
BioNTech and Pfizer are looking to send a hundred million doses of the vaccine this year, enough for another 50 million people to get a two-dose vaccine, and with this source already divided among governments, it would not be enough to protect the United States. States, Array Sahin said. Partners expect to gain initial knowledge of a 44,000-person test next month to see if the vaccine works.
The increase to complete the production capacity will take some time. The new site will be to manufacture 250 million doses of your vaccine in the first part of next year, and up to 750 million doses consistent with the year once it is completely incompatible with the vaccine. The photographs will be used in the Chinese market and other countries around the world, and Pfizer will also produce the vaccine in the United States and Europe.
Together, Pfizer and BioNTech had first stated that they could manufacture more than 1. 3 billion doses of vaccine by the end of next year. Today’s production agreement will increase its joint capacity by at least three hundred million doses according to the year, Mr. . Sahin.
Click here to read that Mint ePapermint is now on Telegram. Join the mint channel in your telegram and updated
Log in to our to save your favorites. It’ll only take a moment.
Your query has expired, reconnect.
You are now subscribed to our newsletters. If you can’t find any email from us, check your spam folder.